A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.
Marotti. Valentina V; Xu. Yining Y; Bohns Michalowski. Cécilia C; Zhang. Wunan W; Domingues. Inês I; Ameraoui. Hafsa H; Moreels. Tom G TG; Baatsen. Pieter P; Van Hul. Matthias M; Muccioli. Giulio G GG; Cani. Patrice D PD; Alhouayek. Mireille M; Malfanti. Alessio A; Beloqui. Ana A
Key Findings
- Hybrid lipid‑hyaluronan‑KPV nanoparticles can carry the GLP‑2 analog teduglutide.
- Adding hyaluronan‑KPV to the particle surface changes its effect on the immune system, providing immunomodulation.
- The platform shows potential for both mucosal healing and immune control in inflammatory bowel disease models.
Practical Outcomes
- For now, the work is purely experimental and not ready for personal use. It suggests that future gut‑health supplements might combine growth‑promoting peptides with immune‑modulating ingredients, but no dosage or protocol can be derived from this study.
Summary
Scientists made tiny particles that can release a gut‑healing peptide (teduglutide) and, if they add a special coating (hyaluronan‑KPV), they can also tweak the immune response. The coating decides whether the particles calm the immune system or not. This is an early‑stage lab concept, not something you can try at home yet.
Abstract
Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface. To this end, we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD. The nanocarriers induced (or did not induce) immunosuppression depending on the presence (or absence) of a hyaluronan-KPV functionalization. This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.
Study Information
pubmed
2023
2023-10-11T00:00:00.000Z
10.1016/j.bioactmat.2023.09.014
21
42